Registry for monitoring heart conditions
The Multicenter Cardiology Monitoring Platform Registry (mCMP-registry)
This study is collecting health information from people with heart symptoms to see if it can help doctors catch heart problems earlier and understand them better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40000 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Maastricht University Medical Center Academic / other |
| Locations | 1 site (Maastricht, Limburg) |
| Trial ID | NCT04976348 on ClinicalTrials.gov |
What this trial studies
The multicenter Cardiology Monitoring Platform registry (mCMP-registry) is a prospective observational registry that collects multi-omics diagnostic measurements as part of routine clinical care. It aims to optimize early diagnosis and risk stratification of cardiovascular diseases, particularly focusing on cardiomyopathy phenotypes, arrhythmias, and coronary artery disease. Participants, aged 16 and older, are referred to cardiology or genetics departments for cardiac symptoms or screening. The registry also includes optional bio-banking and yearly questionnaires to enhance understanding of underlying pathophysiological processes.
Who should consider this trial
Good fit: Ideal candidates for this registry are individuals aged 16 and older who have been referred for cardiac symptoms or screening.
Not a fit: Patients who are unwilling to participate or unable to provide informed consent may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could lead to improved early diagnosis and management of cardiovascular diseases, ultimately enhancing patient outcomes.
How similar studies have performed: Other observational registries focusing on cardiovascular diseases have shown success in improving diagnosis and treatment strategies, indicating potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines(3)) or for cardiac/cardiogenetic screening; * Age ≥16 years. Exclusion Criteria: * Unwillingness to participate or unable to give written informed consent (e.g. due to language barriers or severe intellectual disability).
Where this trial is running
Maastricht, Limburg
- Maastricht UMC+ — Maastricht, Limburg, Netherlands (Recruiting)
Study contacts
- Principal investigator: Hans-Peter Brunner-La Rocca, Prof. — Maastricht University Medical Center
- Study coordinator: Jerremy Weerts, MD
- Email: jerremy.weerts@mumc.nl
- Phone: + 31 43 3871592
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.